Last reviewed · How we verify
NCT04348006: MM
Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Phase 4 trial testing Bortezomib 3.5 MG in Newly Diagnosed Multiple Myeloma. Withdrawn.
30 July 2021
Quick facts
| Lead sponsor | Al-Rasheed University College |
|---|---|
| Phase | Phase 4 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 March 2020 |
| Primary completion | 30 July 2021 |
| Estimated completion | 30 July 2021 |
| Sites | 1 location across Iraq |
Drugs / interventions tested
- Bortezomib 3.5 MG — full drug profile →
Conditions studied
- Newly Diagnosed Multiple Myeloma — all drugs for Newly Diagnosed Multiple Myeloma →
Sponsor
Al-Rasheed University College
Who can join
Adults 18 to 80, any sex, with Newly Diagnosed Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ikaros Proteins in Tumor: Current Perspectives and New Developments.
Xia R, Cheng Y, Han X, Wei Y, et al · · 2021 · cited 12× · PMID 34950704 · DOI 10.3389/fmolb.2021.788440
Verify or expand the search:
- PubMed search for NCT04348006
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Newly Diagnosed Multiple Myeloma
Currently open trials in the same condition.
- NCT06679101 — A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab · Phase 3 · recruiting
- NCT06682156 — Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients · recruiting
- NCT05259553 — Biomarkers in Multiple Myeloma · NA · recruiting
Other Al-Rasheed University College trials
Trials by the same sponsor.
- NCT06549556 — The Value of Using Colostrum Supplements on the Physical Performance and Cognitive Function in Healthy Subjects and Type · Phase 2 · completed
- NCT05918068 — Pyridoxine Effect on the Blood Glucose Level in Type 2 Diabetic Patients · NA · completed
- NCT05981742 — Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activiti · Phase 2 · completed
- NCT06022640 — Educational and Supportive Care to Depressed Infertile Females · NA · completed
- NCT06454643 — Gentamicin in Cardiac Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04348006 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Al-Rasheed University College
- Last refreshed: 28 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04348006.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing